ClinConnect ClinConnect Logo
Search / Trial NCT06087029

IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Launched by DUKE UNIVERSITY · Oct 11, 2023

Trial Information

Current as of August 27, 2025

Recruiting

Keywords

Tevar

ClinConnect Summary

The IMPRoving Outcomes in Vascular DisEase trial is studying a treatment approach for patients with a type of condition called Type B aortic dissection, which is a tear in the aorta that doesn’t involve certain critical areas of the heart. The trial aims to find out if a more invasive treatment called TEVAR (a procedure that helps repair the aorta) combined with medical therapy is better at preventing serious complications or death compared to a more conservative method that relies on just medication and regular check-ups.

To participate in the trial, you must be at least 21 years old, diagnosed with Stanford type B aortic dissection without any ruptures, and be within 48 hours to 6 weeks of your initial hospital visit. The trial is currently looking for participants of all genders. If you join, you’ll be monitored closely, and your doctors will work with you to follow the study’s guidelines. It’s important to know that certain conditions, like ongoing infections or significant health issues unrelated to the aorta, may prevent you from joining the study. If you’re interested, talk to your doctor to see if this trial might be right for you.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age \> 21 years
  • 2. Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
  • 3. Acuity: within 48 hours - 6 weeks of index admission
  • 4. Ability to provide written informed consent and comply with the protocol
  • 5. Investigator believes anatomy is suitable for TEVAR
  • Exclusion Criteria:
  • 1. Ongoing systemic infection
  • 2. Pregnant or planning to become pregnant in the next 3 months
  • 3. Life expectancy related to non-aortic conditions \< 2 years
  • 4. Unwilling or unable to comply with all study procedures including serial imaging follow-up
  • 5. Known patient history of genetic aortopathy
  • 6. Penetrating Aortic Ulcer and Intramural hematoma
  • 7. Iatrogenic (traumatic) aortic dissection
  • 8. Prior surgery for aortic dissection

About Duke University

Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.

Locations

Chicago, Illinois, United States

Rochester, Minnesota, United States

Kansas City, Kansas, United States

Minneapolis, Minnesota, United States

Boston, Massachusetts, United States

Brooklyn, New York, United States

Philadelphia, Pennsylvania, United States

Durham, North Carolina, United States

Birmingham, Alabama, United States

Milwaukee, Wisconsin, United States

San Francisco, California, United States

Columbus, Ohio, United States

Saint Louis, Missouri, United States

Rochester, New York, United States

Camden, New Jersey, United States

Pittsburgh, Pennsylvania, United States

Stanford, California, United States

Springfield, Illinois, United States

Seattle, Washington, United States

Detroit, Michigan, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Omaha, Nebraska, United States

Hartford, Connecticut, United States

Chapel Hill, North Carolina, United States

Stony Brook, New York, United States

Portland, Oregon, United States

Charleston, West Virginia, United States

Tampa, Florida, United States

New York, New York, United States

New Haven, Connecticut, United States

Chicago, Illinois, United States

Aurora, Colorado, United States

Norfolk, Virginia, United States

Salt Lake City, Utah, United States

Columbia, Missouri, United States

Los Angeles, California, United States

Baltimore, Maryland, United States

Syracuse, New York, United States

Worcester, Massachusetts, United States

Ann Arbor, Michigan, United States

Gainesville, Florida, United States

Indianapolis, Indiana, United States

Roslyn, New York, United States

Long Beach, California, United States

Phoenix, Arizona, United States

Scarborough, Maine, United States

Dallas, Texas, United States

Houston, Texas, United States

Newark, New Jersey, United States

Austin, Texas, United States

Plano, Texas, United States

San Diego, California, United States

Colorado Springs, Colorado, United States

Grand Rapids, Michigan, United States

Charlotte, North Carolina, United States

Dallas, Texas, United States

Patients applied

0 patients applied

Trial Officials

Manesh R Patel, M.D.

Principal Investigator

Duke University

Firas F Mussa, M.D.

Principal Investigator

The University of Texas at Houston

Panos Kougias, M.D.

Principal Investigator

The State University of New York at Downstate

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported